Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.52 |
| ▸ | SRC | P12931 | 5/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.52 |
| ▸ | KDR | P35968 | 4/20 | 0.50 |
| ▸ | FLT1 | P17948 | 3/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.49 |
| ▸ | FLT4 | P35916 | 2/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.48 |
| ▸ | CSF1R | P07333 | 4/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168459 | 0.86 | EGFR (0.49) | EGFRSRCERBB2KDRFLT1 | |
| SCHEMBL168061 | 0.84 | SRC (0.38) | EGFRSRCERBB2KDRFLT1 | |
| SCHEMBL6384016 | 0.81 | SRC (0.81) | EGFRSRCERBB2KDRFLT1 | |
| Hydrochloric Acid SCHEMBL6384369 | 0.80 | SRC (0.80) | EGFRSRCERBB2KDRFLT1 | |
| SCHEMBL248872 | 0.75 | PRKDC (0.49) | EGFRSRCKDRMAP2K1PRKDC | |
| SCHEMBL257161 | 0.73 | PRKDC (0.59) | EGFRSRCKDRFLT1FGFR1 | |
| SCHEMBL166327 | 0.73 | PRKDC (0.72) | EGFRSRCKDRPRKDC | |
| SCHEMBL168154 | 0.73 | PRKDC (0.51) | EGFRSRCKDRPRKDC | |
| SCHEMBL6183876 | 0.73 | SRC (0.78) | EGFRSRCERBB2MAP2K1CSF1R | |
| SCHEMBL31439302 | 0.72 | EGFR (0.39) | EGFRSRCERBB2KDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166567-A1 | IMIDAZO[4,5-C]QUINOLINES AS DNA-PK INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2017-06-15 | — | — | US | disclosed |
| US-9598408-B2 | Imidazo[4,5-C]quinolines as DNA-PK inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2017-03-21 | — | — | US | disclosed |
| US-20150203491-A1 | IMIDAZO[4,5-C]QUINOLINES AS DNA-PK INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2015-07-23 | — | — | US | disclosed |
| US-9000153-B2 | Imidazo[4,5-c]quinolines as DNA-PK inhibitors | MERCK PATENT GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| EP-2609082-B1 | IMIDAZO[4,5-C]QUINOLINES AS DNA-PK INHIBITORS | MERCK PATENT GMBH (DE) | 2015-02-18 | — | — | EP | disclosed |
| US-20130172337-A1 | Imidazo[4,5-c]quinolines as DNA-PK inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-04 | — | — | US | disclosed |
| EP-2609082-A1 | IMIDAZO[4,5-C]QUINOLINES AS DNA-PK INHIBITORS | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012028233-A1 | IMIDAZO[4,5-C]QUINOLINES AS DNA-PK INHIBITORS | MERCK PATENT GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166567-A1 | IMIDAZO[4,5-C]QUINOLINES AS DNA-PK INHIBITORS | CHEK1, CHEK2, TTK | EGFR 705/4885SRC 1098/4885ERBB2 660/4885 |
| US-20130172337-A1 | Imidazo[4,5-c]quinolines as DNA-PK inhibitors | CHEK1, CHEK2, TTK | EGFR 705/4885SRC 1098/4885ERBB2 660/4885 |
| US-20150203491-A1 | IMIDAZO[4,5-C]QUINOLINES AS DNA-PK INHIBITORS | CHEK1, CHEK2, TTK | EGFR 705/4885SRC 1098/4885ERBB2 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.